TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03261050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counter Attitudinal Therapy
Description: 8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Therapy
Description: 8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
Study: NCT04918368

Intervention type: BEHAVIORAL
Intervention: Behavioral scales were used
Description: Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
Study: NCT02150837

Intervention type: OTHER
Intervention: 5 & 2 & 2 Plan
Description: Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, \>72g protein, \>100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
Study: NCT03378297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets 850 mg x 2 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid tablets 160 mg x1 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib capsules 300 mg x 2 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozol tablets 2.5 mg x 1 orally
Study: NCT03613909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP950 OTE Sound processor
Description: CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
Study: NCT00502892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.5 mg/m\^2 IV Daily x 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1.8 grams/m\^2 IV Over 1 Hour x 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days \[for patients \> 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days\]
Study: NCT01188824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: 100 mg, bid p.o.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet, bid
Study: NCT02150837

Intervention type: OTHER
Intervention: 4 & 2 & 1 Plan
Description: Medifast has developed the 4 \& 2 \& 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 \& 2 \& 1 Plan consists of 4 Medifast meal replacements, 2 Lean \& Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, \>72g protein, \>100g carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
Study: NCT02539836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nutrition based on plant fermentation extract
Description: The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI in quantifying liver fat with MRS
Description: To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
Study: NCT02714101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine assisted occupational therapy
Description: Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
Study: NCT02329301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDA with DHAp (Eurartesim)
Description: Eurartesim is the brand name.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Focal MDA with DHAp (Eurartesim)
Description: Eurartesim is the brand name.
Study: NCT02475317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Participants will receive volixibat in 10 mg and 20 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Participants will receive volixibat in 10 mg and 20 mg doses.
Study: NCT02302131

Intervention type: OTHER
Intervention: SAPIEN XT
Description: Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
Study: NCT00873665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: wait-list control
Description: To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
Study: NCT00214825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: 50 mg daily for 6 weeks with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrochlorothiazide
Description: HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
Study: NCT02206295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag
Study: NCT00659984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UltratraceTM Iobenguane I 131 Imaging
Description: 0.1 mCi/kg \[3.7 MBq/kg\] (minimum dose 1mCi \[37MBq\] but not to exceed 5 mCi \[185 MBq\]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UltratraceTM Iobenguane I 131 Therapy
Description: Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed \> 23 Gy to the kidneys, \> 30 Gy to the liver, or \> 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
Study: NCT00500240

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Glargine
Description: Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
Study: NCT02752165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAM-ED
Description: Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
Study: NCT00500240

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart
Description: Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
Study: NCT06018909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Interventions Package
Description: CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
Study: NCT04315532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva samples
Description: Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva samples
Description: Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GCF samples
Description: GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GCF samples
Description: GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
Study: NCT00325221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM on
Description: Home Monitoring activated after implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM Off
Description: Home Monitoring activated 9 months after implantation
Study: NCT01347385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy with unidirectional barbed suture
Description: Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional suture material
Description: Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
Study: NCT03155932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD334
Description: APD334 active treatment for 24 weeks.
Study: NCT02752165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Report of symptoms to primary care physician
Study: NCT04079192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus A9 Drug Coated Balloon
Description: A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent Please Paclitaxel Drug Coated Balloon
Description: A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
Study: NCT01354743

Intervention type: DRUG
Group type: OTHER
Intervention: Dysport
Description: Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits.

Intervention type: DEVICE
Group type: OTHER
Intervention: Perlane L
Description: The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
Study: NCT01595412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Resection Rectopexy
Description: laparoscopic sigmoidectomy with suture rectopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Ventral Rectopexy
Description: laparoscopic ventral rectopexy with mesh
Study: NCT00737425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PainShield

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PainShield
Study: NCT01672853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Subcutaneous injections weekly for a total of 96 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Subcutaneous injections weekly for a total of 96 injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections weekly for a total of 96 injections
Study: NCT01145807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDT067
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Transfersome
Description: Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
Study: NCT01287520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
Study: NCT01630720

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C or vitamin D
Description: vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C or vitamin D
Description: vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
Study: NCT00288301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: weight loss intervention
Study: NCT02046395

Intervention type: DRUG
Group type: OTHER
Intervention: amlodipine, hydralazine, terazosin or hydrochlorothiazide
Description: In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
Study: NCT02567825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tube placement
Description: As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Clavulanate and/or Ceftriaxone
Description: Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin Otic
Description: Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
Study: NCT02895022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% adrénalinée

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caesarean section
Study: NCT00365378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: HPV 16 L1 Vaccine
Description: A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
Study: NCT01212536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscopy
Description: laryngoscopy and intubation
Study: NCT01276561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Incision Splenectomy
Description: Patients will undergo laparoscopic splenectomy through a single incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Splenectomy
Description: Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
Study: NCT02943889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
Study: NCT03008525

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous and visceral adipose tissue biopsies
Description: Subcutaneous and visceral adipose tissue biopsies during operation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous and visceral adipose tissue biopsies
Description: Subcutaneous and visceral adipose tissue biopsies during operation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples analysis
Description: Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples analysis
Description: Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin.